TAILIEUCHUNG - The effects of sitagliptin add on on insulin resistance, beta cell function in patients with type 2 diabetes who were taking oral hypoglycemic agent

Objectives: To evaluate the effects of sitagliptin add-on on insulin resistance and beta cell function in patients with type 2 diabetes who were taking other oral hypoglycemic agent(s). Subjects and method: 101 patients with type 2 diabetes mellitus diagnosed by WHO (1998) criteria, who were taking hypoglycemic agent(s) other than dipeptidyl peptidase-4 inhibitors. | Journal of military pharmaco-medicine n08-2018 THE EFFECTS OF SITAGLIPTIN ADD-ON ON INSULIN RESISTANCE, BETA CELL FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WHO WERE TAKING ORAL HYPOGLYCEMIC AGENT Le Thi Viet Ha1; Doan Van De2 SUMMARY Objectives: To evaluate the effects of sitagliptin add-on on insulin resistance and beta cell function in patients with type 2 diabetes who were taking other oral hypoglycemic agent(s). Subjects and method: 101 patients with type 2 diabetes mellitus diagnosed by WHO (1998) criteria, who were taking hypoglycemic agent(s) other than d ipeptidyl peptidase-4 inhibitors. The study compared insulin resistance and beta-cell function assessed with HOMA2 before and after sitagliptin to other oral hypoglycemic agent(s) in type 2 diabetic patients for those 2 periods: Received 50 mg of sitagliptin for week 1 to 12, and 100 mg for week 13 to 24. Results: The mean age was ± years old, the female and male mad up and , respectively. The mean fasting plasma glucose and HbA1c was ± mmoL/L and ± , respectively. After 24 weeks, fasting plasma glucose, HbA1c and fasting plasma C -peptide level decreased by ± mmoL/L, ± and ± 8 nmoL/L, respectively. The HOMA2-IR assessed by C-peptide (HOMA2-IR-Cp) decreased by ± and HOMA % B assessed by C-peptide (HOMA2- %B-Cp) increased by ± . All the changes were statistically significant. After 24 weeks, the percentage of patients with increased HOMA2-IR-Cp decreased from (baseline) to , and the percentage of patients with decreased HOMA2-%B-Cp decreased from to . The both changes were statistically significant. Conclusion: Sitagliptin addition to other hypoglycemic agent(s) in patients with type 2 diabetes improved beta-cell function and decreased insulin resistance along with improved blood glucose levels. * Keywords: Type 2 diabetes; Sitagliptin; Insulin resistance; Beta cell .

• Y khoa - Dược
• Type 2 diabetes
• Insulin resistance
• Beta cell function
• Oral hypoglycemic agent
• Dipeptidyl peptidase 4 inhibitors
• Hypoglycemic agent
• Prevalence of type 2 diabetes
• Risk factors for type 2 diabetes
• Type 2 diabetes causes
• Associated factors of type 2 diabetes
• diabetes
• diabetes treatment
• diabetes prevention
• Oral Diabetes Medications
• Adults With Type 2 Diabetes
• Changing self care knowledge
• The outpatients with Type 2 diabetes
• Yenbai provincal hospital
• Type 2 diabetes for outpatient examination
• BMC Cancer
• Within class differences
• Patients with type 2 diabetes
• Cancer risk
• Weight gain
• Thiazolidinediones in type 2
• Type 2 diabetes mellitus
• TZDs exert weight gain
• Mechanism of TZDs on weight gain
• Diabetes mellitus patients
• Quality of life
• Life among out patients
• Type 2 diabetes managed
• QOL in this patient group
• Knowledge on the diet
• Practice on diet
• Outpatients with type 2 diabetes
• General information
• Drug use
• Agricultural Hospital
• Pre designed questionnaires
• Treatment of diabetes
• International Diabetes Federation
• Breast cancer
• Diabetes mellitus
• Female diabetes
• Cox regression
• Casein Kinase 2 Alpha 1
• Real time quantitative polymerase chain reactions
• Enzyme linked immunosorbent
• Protein complex
• Diabetes related protein complex
• Polyacrylamide gel electrophoresis
• Immunoinflammation related protein complexes
• Self care
• Self assessment questionnaires
• Diabetes self care
• Physical activity
• Risk factors
• Cancer development
• Diabetes duration
• Body mass index
• BMC Musculoskeletal Disorders
• Healthcare resource utilization
• Hospital claims database analysis
• Raloxifene hydrochloride
• Retrospective cohort study
• Prostate cancer diagnosis
• Gonadotropin releasing hormone agonists
• Prostate cancer
• BMC Geriatrics
• Myocardial infarction
• Impaired fasting glucose
• Glucose tolerance
• Laryngeal cancer
• C peptide
• Proliferative diabetic retinopathy
• Diabetic nephropathy
• Bariatric surgery
• Intensive insulin therapy
• Diabetes complications
• Glycemic control
• Retrospective study
• Dipeptidyl peptidase inhibitor
• Oral antidiabetic drug
• DPP 4 inhibitors
• Type 2 diabetes inadequately
• BMC Pediatrics
• Extract of Gingko biloba
• High fat diet
• Pancreatic β cells
• BMC Pharmacology and Toxicology
• Remogliflozin etabonate
• Sodium dependent glucose transporter 2 inhibitor
• Lower plasma glucose
• Tạp chí khoa học
• Tạp chí y dược
• Y dược quân sự
• Diet pattern
• Plasma leptin level